FDA: Mifepristone review won’t be done until March

The FDA's announcement that it won't complete its safety review of the abortion drug mifepristone until March has sparked frustration among anti-abortion activists, who've been pushing for quicker decisions. The FDA clarified it won't impose new restrictions before March, which is a relief for pro-choice advocates who rely on the drug. This delay underscores the ongoing contentious debate around abortion rights and the regulatory process, highlighting how administrative timelines can deeply affect public policy and social issues.